Effect of targeted biopsy guided by elastic image fusion of MRI with 3D-TRUS on diagnosis of anterior prostate cancer

被引:23
|
作者
Baco, Eduard [1 ]
Rud, Erik [2 ]
Ukimura, Osamu [1 ]
Vlatkovic, Ljiljana [3 ]
Svindland, Aud [3 ]
Matsugasumi, Toru [1 ]
Bernhard, Jean-Christophe [4 ]
Rewcastle, John C. [1 ]
Eggesbo, Heidi B. [5 ]
机构
[1] Univ So Calif, Keck Sch Med, USC Inst Urol, Los Angeles, CA 90033 USA
[2] Oslo Univ Hosp Aker, Dept Radiol, Oslo, Norway
[3] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Pathol, Oslo, Norway
[4] Univ Bordeaux 1, Chirurg Urol & Transplantat Renale CHU Bordeaux, INSERM U1029, F-33405 Talence, France
[5] Oslo Univ Hosp, Dept Radiol & Nucl Med, Oslo, Norway
关键词
Clinically significant prostate cancer; Magnetic resonance imaging; Transrectal ultrasound; Elastic image fusion; Targeted prostate biopsy; TRANSRECTAL ULTRASOUND GUIDANCE; FEATURES; SYSTEM;
D O I
10.1016/j.urolonc.2014.07.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the effect of targeted biopsy (TB) with elastic fused magnetic resonance imaging (MRI) and 3-dimensional transrectal ultrasound (3D-TRUS) guidance in the diagnosis of anterior prostate cancer (APCa). Material and method: A retrospective study was performed on patients who underwent TB with elastic fused MRI/3D-TRUS guidance using a 1.5-T MRI with T2- and diffusion-weighted images. APCa was defined as TB-proven cancer whose MR-imaged center was located anteriorly according to standardized MRI reporting schema. Prostate Imaging Reporting and Data System was used to quantify MRI suspicion. Maximum cancer core length (MCCL), cancer core involvement, primary Gleason grade pattern, and Gleason score (GS) on TB were assessed. A clinically significant cancer on TB was MCCL >= 5 mm of GS 6 or any cancer with GS >= 7. Agreement between TB and radical prostatectomy step sections was assessed for all subjects when possible. Results: A total of 211 consecutive subjects were included. APCa was found in 81% (170/211). Median (range) of TB per patient, MCCL, and cancer core involvement were 2 (1-5), 10 mm (4-23), and 57% (10%-100%), respectively. According to the level of MRI suspicion, positive rate for any cancer vs. clinically significant cancer was 96% (114/119) vs. 86% (102/119) for highly suspicious, 80% (46/57) vs. 68% (39/57) for likely, and 29% (10/35) vs. 20% (7/35) for equivocal, respectively (P = 0.016 and <0.001). Step-section analysis was possible for 70 patients. Concordance of primary Gleason grade pattern and GS between TB and radical prostatectomy was 90% (kappa = 0.7) and 77% (kappa = 0.64), respectively. Conclusion: TB with elastic fused MRI/3D-TRUS guidance significantly enhanced accuracy in diagnosing clinically significant APCa. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:1300 / 1307
页数:8
相关论文
共 50 条
  • [31] Sextant vs targeted transrectal ultrasound (TRUS) guided biopsy for prostate cancer
    Kuligowska, E
    Barish, MA
    Blake, MA
    Fenlon, HM
    RADIOLOGY, 2000, 217 : 559 - 559
  • [32] ABSENCE OF LEARNING CURVE IMPACT MAY LET MRI-TRUS FUSION GUIDED BIOPSY UP FOR EARLY DIAGNOSIS OF PROSTATE CANCER
    Lista, Giuliana
    Lughezzani, Giovanni
    Lazzeri, Massimo
    Bini, Vittorio
    Hurle, Rodolfo
    Buffi, Nicolo
    Cardone, Pasquale
    Pasini, Luisa
    DeZorzi, Silvia Zandegiacomo
    Peschechera, Roberto
    Bozzini, Giorgio
    Maffei, Davide
    Guazzoni, Giorgio
    JOURNAL OF UROLOGY, 2017, 197 (04): : E27 - E27
  • [33] Robot-assisted 3D-TRUS guided prostate brachytherapy: System integration and validation
    Wei, ZP
    Wan, G
    Gardi, L
    Mills, G
    Downey, D
    Fenster, A
    MEDICAL PHYSICS, 2004, 31 (03) : 539 - 548
  • [34] CAN SYSTEMATIC BIOPSY BE SAFELY OMITTED IN THE ERA OF MRI/TRUS-FUSION TARGETED PROSTATE BIOPSY?
    Nakanishi, Yasukazu
    Fukushima, Hiroshi
    Yokoyama, Minato
    Kataoka, Madoka
    Tobisu, Ken-ichi
    Koga, Fumitaka
    JOURNAL OF UROLOGY, 2016, 195 (04): : E167 - E167
  • [35] Prostate Cancer: Targeted Fusion Biopsy with multiparametric MRI
    von Hardenberg, Jost
    Westhoff, Niklas
    AKTUELLE UROLOGIE, 2019, 50 (05) : 473 - 474
  • [36] Prostate MRI and transperineal TRUS/MRI fusion biopsy for prostate cancer detection: clinical practice updates
    Martorana, Eugenio
    Pirola, Giacomo Maria
    Aisa, Maria Cristina
    Scialpi, Pietro
    Di Blasi, Aldo
    Saredi, Giovanni
    D'Andrea, Alfredo
    Signore, Stefano
    Grisanti, Riccardo
    Scialpi, Michele
    TURKISH JOURNAL OF UROLOGY, 2019, 45 (04): : 237 - 244
  • [37] PSMA-PET MRI/TRUS robot-guided targeted prostate biopsy for detection and localisation of Primary prostate cancer
    Mix, M.
    Schaal, K.
    Kroenig, M.
    Drendel, V.
    Wetterauer, U.
    Schultze-Seemann, W.
    Jilg, C. A.
    Meyer, P. T.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S403 - S403
  • [38] Cancer Detection Rates in Targeted Transperineal MRI-TRUS Elastic Fusion-guided Prostate Biopsies Performed Under Local Anesthesia
    Jacewicz, Maciej
    Rud, Erik
    Galtung, Kristina Flor
    Noor, Daniyal
    Baco, Eduard
    ANTICANCER RESEARCH, 2021, 41 (09) : 4395 - 4400
  • [39] 3D Navigo™ versus TRUS-guided prostate biopsy in prostate cancer detection
    Gayet, Maudy
    van der Aa, Anouk
    Schmitz, Peter
    Beerlage, Harrie P.
    Schrier, Bart Ph.
    Mulders, Peter F. A.
    Mischi, Massimo
    Wijkstra, Hessel
    WORLD JOURNAL OF UROLOGY, 2016, 34 (09) : 1255 - 1260
  • [40] THE ROLE OF THE OPERATOR IN THE CANCER DETECTION WITH MRI/TRUS FUSION TRANSRECTAL PROSTATE BIOPSY
    Porpiglia, Francesco
    Cossu, Marco
    De Luca, Stefano
    Manfredi, Matteo
    Mele, Fabrizio
    Bertolo, Riccardo
    Amparore, Daniele
    Checcucci, Enrico
    Garrou, Diletta
    De Pascale, Agostino
    Russo, Filippo
    Fiori, Cristian
    JOURNAL OF UROLOGY, 2018, 199 (04): : E1028 - E1028